Australia Leads The Way In Biosimilar Substitution With Inflectra Listing
This article was originally published in SRA
Executive Summary
The Australian government has announced that Hospira's Inflectra, a biosimilar version of infliximab, is being subsidized under the Pharmaceutical Benefits Scheme as of Dec. 1, 2015, and that pharmacists will be able to substitute it for the reference product, Johnson & Johnson's Remicade1.